Raffles Medical Group Ltd BSL
SGX · Singapore · Health Services
SGD 0.8200-0.01 (-1.20%)
Market closed· · SGD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · SGD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced today that it has signed a supply agreement with Raffles Medical for its neurodegenerative brain imaging analysis software, Neurophet AQUA.
Potential Raffles Medical Group Ltd ( SGX:BSL ) shareholders may wish to note that the Executive Chairman & CEO, Choon...
Raffles Medical Group Ltd ( SGX:BSL ) stock is about to trade ex-dividend in four days. Typically, the ex-dividend date...
In April 2026, global markets have experienced notable fluctuations, with major U.S. stock indexes reaching record highs due to positive economic data and strong performances in AI-linked stocks despite geopolitical tensions. The Russell 2000 Index, a key measure for small-cap stocks, has shown resilience with a year-to-date increase of over 12%, highlighting investor interest in smaller companies amid rising retail sales and robust corporate earnings. In this dynamic environment,...
Raffles Medical Group (the Group) and Gene Solutions have signed a Memorandum of Understanding (MOU) on 22 October 2025 to streamline patient recruitment for oncology clinical trials, marking a significant milestone in advancing precision medicine in Southeast Asia.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.